The Prognostic Relevance of FOXA1 and Nestin Expression in Breast Cancer Metastases: a Retrospective Study of 164 Cases During a 10-year Period (2004-2014)

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Mar 2

PMID 30819139

Citations 6

Authors

Shahin De Lara

Jenny Nyqvist

Elisabeth Werner Ronnerman

Khalil Helou

Elisabeth Kenne Sarenmalm

Zakaria Einbeigi

Per Karlsson

Toshima Z Parris

Aniko Kovacs

Affiliations

Soon will be listed here.

Abstract

Background: Current prognostic markers cannot adequately predict the clinical outcome of breast cancer patients. Therefore, additional biomarkers need to be included in routine immune panels. FOXA1 was a significant predictor of favorable outcome in primary breast cancer, while Nestin expression is preferentially found in triple-negative tumors with increased rate of nodal metastases, and reduced survival. No studies have investigated the prognostic value of FOXA1 and Nestin expression in breast cancer metastases.

Methods: Breast cancer metastases (n = 164) from various anatomical sites were retrospectively analyzed by immunohistochemistry for FOXA1, Nestin and GATA3 expression. Cox regression analysis assessed the prognostic value of FOXA1 and Nestin expression.

Results: In breast cancer metastases, FOXA1 expression was associated with Nestin-negativity, GATA3-positivity, ER-positivity, HER2-positivity and non-triple-negative status (P < 0.05). In contrast, Nestin expression was associated with FOXA1-negative, GATA3-negative, ER-negative, and triple-negative metastases (P < 0.05). Univariate Cox regression analysis showed FOXA1 expression was predictive of overall survival (OS, P = 0.00048) and metastasis-free survival (DMFS, P = 0.0011), as well as, distant metastasis-free survival in ER-positive patients (P = 0.036) and overall survival in ER-negative patients (P = 0.024). Multivariate analysis confirmed the significance of FOXA1 for both survival endpoints in metastatic breast cancer patients (OS, P = 0.0033; DMFS, P = 0.015).

Conclusions: In our study, FOXA1 was expressed mostly in ER-positive breast cancer metastases. Expression of Nestin was related to triple-negative metastases, where brain was the most frequent metastatic site. These findings highlight the clinical utility of FOXA1 and Nestin expression and warrant their inclusion in routine immunohistochemical panels for breast carcinoma.

Citing Articles

Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.

Goglia A, Alshalalfa M, Khan A, Isakov D, Hougen H, Swami N J Natl Cancer Inst. 2024; 117(1):188-197.

PMID: 39254651 PMC: 11717412. DOI: 10.1093/jnci/djae224.

FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.

Liu Y, Yu K, Kong X, Zhang K, Wang L, Zhang N Sci Adv. 2023; 9(33):eadg7112.

PMID: 37595040 PMC: 10438466. DOI: 10.1126/sciadv.adg7112.

FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact.

Metovic J, Borella F, DAlonzo M, Biglia N, Mangherini L, Tampieri C Cancers (Basel). 2022; 14(19).

PMID: 36230619 PMC: 9564251. DOI: 10.3390/cancers14194699.

LncRNA ENST869 Targeting Nestin Transcriptional Region to Affect the Pharmacological Effects of Chidamide in Breast Cancer Cells.

Feng X, Han H, Guo Y, Feng X, Guo S, Zhou W Front Oncol. 2022; 12:874343.

PMID: 35444938 PMC: 9014306. DOI: 10.3389/fonc.2022.874343.

The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications.

Qin S, Mao Y, Wang H, Duan Y, Zhao L Int J Biol Sci. 2021; 17(11):2718-2736.

PMID: 34345203 PMC: 8326131. DOI: 10.7150/ijbs.60641.

References

Thorat M, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho J . Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol. 2007; 61(3):327-32. DOI: 10.1136/jcp.2007.052431. View

Habashy H, Powe D, Rakha E, Ball G, Paish C, Gee J . Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer. 2008; 44(11):1541-51. DOI: 10.1016/j.ejca.2008.04.020. View

Parry S, Savage K, Marchio C, Reis-Filho J . Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol. 2008; 61(9):1045-50. DOI: 10.1136/jcp.2008.058750. View

Nakshatri H, Badve S . FOXA1 in breast cancer. Expert Rev Mol Med. 2009; 11:e8. DOI: 10.1017/S1462399409001008. View

Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J . Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res. 2009; 11(3):R40. PMC: 2716509. DOI: 10.1186/bcr2327. View

Ademuyiwa F, Thorat M, Jain R, Nakshatri H, Badve S . Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol. 2009; 23(2):270-5. DOI: 10.1038/modpathol.2009.172. View

Robbins C, Tembe W, Baker A, Sinari S, Moses T, Beckstrom-Sternberg S . Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2010; 21(1):47-55. PMC: 3012925. DOI: 10.1101/gr.107961.110. View

Mehta R, Jain R, Leung S, Choo J, Nielsen T, Huntsman D . FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat. 2011; 131(3):881-90. DOI: 10.1007/s10549-011-1482-6. View

Augello M, Hickey T, Knudsen K . FOXA1: master of steroid receptor function in cancer. EMBO J. 2011; 30(19):3885-94. PMC: 3209791. DOI: 10.1038/emboj.2011.340. View

10.

Piras F, Ionta M, Lai S, Perra M, Atzori F, Minerba L . Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer. Eur J Histochem. 2012; 55(4):e39. PMC: 3284241. DOI: 10.4081/ejh.2011.e39. View

11.

Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S . Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer. 2012; 3(4):147-59. PMC: 10358124. DOI: 10.1007/s12672-012-0111-0. View

12.

Barbieri C, Baca S, Lawrence M, Demichelis F, Blattner M, Theurillat J . Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012; 44(6):685-9. PMC: 3673022. DOI: 10.1038/ng.2279. View

13.

Grasso C, Wu Y, Robinson D, Cao X, Dhanasekaran S, Khan A . The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406):239-43. PMC: 3396711. DOI: 10.1038/nature11125. View

14.

Robinson J, Holmes K, Carroll J . FOXA1 mutations in hormone-dependent cancers. Front Oncol. 2013; 3:20. PMC: 3572741. DOI: 10.3389/fonc.2013.00020. View

15.

Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y . FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer. 2013; 22(3):308-16. DOI: 10.1007/s12282-013-0482-2. View

16.

Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y . Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. Breast Cancer. 2014; 22(5):520-8. DOI: 10.1007/s12282-013-0515-x. View

17.

Hu Q, Luo Z, Xu T, Zhang J, Zhu Y, Chen W . FOXA1: a promising prognostic marker in breast cancer. Asian Pac J Cancer Prev. 2014; 15(1):11-6. DOI: 10.7314/apjcp.2014.15.1.11. View

18.

Horimoto Y, Arakawa A, Harada-Shoji N, Sonoue H, Yoshida Y, Himuro T . Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases. Br J Cancer. 2014; 112(2):345-51. PMC: 4453454. DOI: 10.1038/bjc.2014.595. View

19.

Zhang G, Zhao Y, Liu Y, Kao L, Wang X, Skerry B . FOXA1 defines cancer cell specificity. Sci Adv. 2016; 2(3):e1501473. PMC: 4803482. DOI: 10.1126/sciadv.1501473. View

20.

Feng W, Liu S, Zhu R, Li B, Zhu Z, Yang J . SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells. Biochem Biophys Res Commun. 2017; 485(2):522-528. DOI: 10.1016/j.bbrc.2017.02.014. View